Item no. |
TMO-T21023-100mg |
Manufacturer |
TargetMol
|
CASRN |
845533-86-0 |
Amount |
100 mg |
Quantity options |
100 mg
1 mL x 10 mM (in DMSO)
10 mg
1 mL
200 mg
25 mg
2 mg
500 mg
50 mg
5 mg
|
Category |
|
Type |
Molecules |
Specific against |
other |
Purity |
99.77% |
Citations |
Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, Padanilam X, Enwerem M, Chotoo S, Singh N, Hughes J, Variava E, Ferreira H, Te Riele J, Ismail N, Mohr E, Bantubani N, Conradie F. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 Oct 25. pii: 1801528. doi: 10.1183/13993003.01528-2018. [Epub ahead of print] PubMed PMID: 30361246. |
Smiles |
OC(=O)\C=C\C(O)=O.COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12 |
ECLASS 10.1 |
32169090 |
ECLASS 11.0 |
32169090 |
UNSPSC |
12000000 |
Alias |
R-403323, R 403323, R403323, TMC 207, TMC207, TMC-207 |
Shipping condition |
Cool pack |
Available |
|
Manufacturer - Targets |
Antibiotic|||Antibacterial |
Shipping Temperature |
cool pack |
Storage Conditions |
-20° |
Molecular Weight |
671, 59 |
Target names or alias |
R 403323 , R-403323 , R403323 , TMC 207 , TMC-207 , TMC207 |
Description |
Bedaquiline fumarate (TMC207), a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections. It blocks the proton pump for ATP synthase of mycobacteria. It is the first member of a new class of drugs called diarylquinolines. |
Pathways |
Microbiology/Virology |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.